Trump demanded that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

President Trump on Thursday sent letters to 17 of the world’s largest drug companies, telling them to take more steps to ...

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo ...

Trump specifically asked that those companies offer the MFN price to Medicaid recipients and to promise that they wouldn't ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Live Updates Live Coverage Updates appear automatically as they are published. MassterCard Charges Ahead 10:00 am In further ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...